KALA PHARMACEUTICALS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $27.9M

Website

Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With DED

Phase 3

Completed

Conditions: Kerato Conjunctivitis Sicca

Interventions: Drug: KPI-121 Ophthalmic Suspension
Drug: Vehicle

First Posted Date: 2018-08-06

Last Posted Date: 2021-04-02

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 901

Registration Number: NCT03616899

Locations: 🇺🇸
Investigator #278, Dothan, Alabama, United States
🇺🇸
Investigator #213, Westminster, California, United States
🇺🇸
Investigator #268, Roswell, Georgia, United States

and more 78 locations

KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children

Phase 3

Terminated

Conditions: Ocular Inflammation

Interventions: Drug: Prednisolone acetate
Drug: KPI-121 1%

First Posted Date: 2018-07-24

Last Posted Date: 2020-10-19

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 2

Registration Number: NCT03596723

Locations: 🇺🇸
Children's Eye Care, PC, Detroit, Michigan, United States
🇺🇸
Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸
Houston Eye Associates, The Woodlands, Texas, United States

and more 1 locations

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Keratoconjunctivitis Sicca
Dry Eye Syndromes

Interventions: Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug: KPI-121 0.25% Ophthalmic Suspension

First Posted Date: 2016-06-30

Last Posted Date: 2021-01-05

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 909

Registration Number: NCT02819284

Locations: 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸
Hernando Eye Institute, Brooksville, Florida, United States
🇺🇸
Shettle Eye Research, Inc, Largo, Florida, United States

and more 59 locations

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Keratoconjunctivitis Sicca
Dry Eye Syndromes

Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension
Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension

First Posted Date: 2016-06-24

Last Posted Date: 2021-02-03

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 918

Registration Number: NCT02813265

Locations: 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸
Schwartz Laser Eye Center, Scottsdale, Arizona, United States
🇺🇸
Eyecare Arkansas, P.A., Little Rock, Arkansas, United States

and more 57 locations

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Phase 3

Completed

Conditions: Post Surgical Ocular Inflammation and Pain

Interventions: Drug: KPI-121 1% Ophthalmic Suspension dosed BID
Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID

First Posted Date: 2016-06-08

Last Posted Date: 2020-12-16

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 520

Registration Number: NCT02793817

Locations: 🇺🇸
Apex Eye, Cincinnati, Ohio, United States
🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
Arizona Eye Center, Chandler, Arizona, United States

and more 32 locations

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

Not Applicable

Completed

Conditions: Retinal Vein Occlusion
Diabetic Macular Edema

Interventions: Drug: KPI-121 1.0% Ophthalmic Suspension
Drug: KPI-121 0.25% Ophthalmic Suspension

First Posted Date: 2014-09-19

Last Posted Date: 2020-12-10

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 16

Registration Number: NCT02245516

Locations: 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

Phase 2

Completed

Conditions: Blepharitis

Interventions: Drug: Vehicle
Drug: KPI-121

First Posted Date: 2014-08-18

Last Posted Date: 2021-01-11

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 206

Registration Number: NCT02218489

Locations: 🇺🇸
Abrams Eye Center, Cleveland, Ohio, United States
🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
Wolstan & Goldberg Eye Associates, Torrance, California, United States

and more 5 locations

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions: Drug: Placebo
Drug: KPI-121

First Posted Date: 2014-07-11

Last Posted Date: 2021-01-06

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 150

Registration Number: NCT02188160

Locations: 🇺🇸
Eye Center of Southern CT, P.C., Hamden, Connecticut, United States
🇺🇸
Total Eye Care, PA, Memphis, Tennessee, United States
🇺🇸
Martel Eye Medical Group, Rancho Cordova, California, United States

and more 8 locations

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

Phase 3

Completed

Conditions: Ocular Infections, Irritations and Inflammations

Interventions: Drug: Vehicle of KPI-121 0.25%
Drug: Vehicle of KPI-121 1.0%
Drug: KPI-121 0.25%
Drug: KPI-121 1.0%

First Posted Date: 2014-06-16

Last Posted Date: 2021-01-29

Lead Sponsor: Kala Pharmaceuticals, Inc.

Target Recruit Count: 380

Registration Number: NCT02163824

Locations: 🇺🇸
Westside Research, LLC, Spartanburg, South Carolina, United States
🇺🇸
Price Vision Group, Indianapolis, Indiana, United States
🇺🇸
Sall Research Medical Center, Artesia, California, United States

and more 20 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy